structural heart News
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TVT 2019
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Annual Transcatheter Valve Therapy Structural Heart Summit (TVT 2019), which will take place June 12-15 at the Sheraton Grand Chicago. The company’s Tempo Temporary Pacing Lead will be featured in a symposium titled “Improving Safety & Reducing ...
-
Moray Featured on Medtech Chat
Co-founder Mark Barrish appeared on MedTech Chat with Tom Donnelly, to discuss how Moray Medical is bringing the benefits of robotics to structural heart repair. (Linked page includes both podcast audio and written ...
-
Moray named one of “6 best” structural heart innovators
CM Medical included Moray Medical’s technology in their “6 of the Best in Structural Heart” roundup. “They’ve made a robot which has less than 200 mechanical parts end to end, which is extremely unusual for the robotic medical device market.” Author James Christopher points out. “With leaders boasting companies like Intuitive and Accuray on their resumes, ...
-
Colibri Heart Valve Forms a New Entity to Monetize Tissue Processing Technology in Applications Outside of Structural Heart
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue ...
-
Colibri Heart Valve Forms a New Entity to Monetize Tissue Processing Technology in Applications Outside of Structural Heart
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue ...
-
iVascular SLU, Barcelona Invests in NaviGate Cardiac Structures, Inc.
At the end of 2018, iVascular SLU, a European medical device company, made an investment in NaviGate Cardiac Structures, Inc. and will be instrumental in helping the company’s developments by providing its expertise in fabrication and manufacturing of various components of our atrioventricular valved stent bioprosthesis system. This will be a very fruitful association that will ...
-
BIOMODEX Technology Enables New Milestone in Interventional Cardiology
BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL. Physicians at the Montreal Heart Institute in Montreal, Quebec recently rehearsed the ...
By BIOMODEX
-
1st MitraClip Procedure Guided by 4D Performed at UC Davis Health
Sacramento, CA – The first MitraClip procedure using EchoPixel’s Holographic Therapy Guidance (HTG) was performed by Structural Heart Physicians at UC Davis Health. The image acquisition was led by Edris Aman M.D. while the procedure was performed and HTG guidance utilized by Gagan Singh, M.D., director, Cardiovascular Research Unit. MitraClip is a procedure that approximates ...
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2017
BioTrace Medical, Inc., today announced the company’s key activities at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 meeting, which will take place October 29 - November 2 at the Colorado Convention Center in Denver. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled: “The Tempo Temporary Pacing Lead: A New Standard of Care in ...
-
JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited
JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited (HKEX: 9996) in China. Under the terms of the agreement, Peijia has made a cash and equity investment in ...
-
1st Successful Heart Tumor Removal Without Open Heart Surgery
EchoPixel has once again contributed to a pioneering procedure at CentraCare – St. Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure ...
-
World’s First Watchman ProcedurewWithout the Use of Contrast Dye
Procedure removes risk of kidney injury or complications in patients with advanced kidney disease or allergy to contrast dye On Sept. 30, CentraCare completed the world’s first contrast-free WATCHMAN implant using 4D holographic therapy guidance, developed by EchoPixel, as the alternative imaging modality. Rather than relying on contrast dye and X-ray based imaging to help guide the ...
-
Sonia Madigan of the Market Herald interviews CEO Wayne Paterson on the progress of Anteris Technologies
Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise On Thursday, the company entered a trading halt, pausing shares until Monday, August 2 It is unknown how much the company is planning to raise or where the funds will be spent On the market, Anteris last traded at $8.59 per share Anteris Technologies (AVR) has paused trading as it plans for an upcoming ...
-
BioTrace Medical Announces Key Events Featuring Tempo Temporary Pacing Lead at TCT 2019
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place September 25-29 in San Francisco. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled “Keeping the Rhythm with the ...
-
InnovHeart raises $55 million in Series C financing to further develop the Trans-septal Saturn Transcatheter Mitral Valve Replacement System
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in ...
-
SafeHeal appoints medical device industry veteran Chris Richardson as Chief Executive Officer
PARIS, France/Tampa, FL – July, 11, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately. Richardson has over 30 years of experience in the medical device industry, and an extensive ...
By SafeHeal
-
BIOMODEX and Montreal Heart Institute Team Up to Develop 3D Printed Pulsatile Heart Models
BIOMODEX®, the leader in biorealistic haptic simulators for physician training and rehearsals, and the Montreal Heart Institute (MHI), a world-renowned, ultra-specialized cardiology center, announced they are partnering to develop a new cardiovascular training solution to help cardiologists rehearse and train for complex valve-in-valve procedures. The teams will collaborate to develop ...
By BIOMODEX
-
Safety and Effectiveness of BioTrace Medical’s Tempo® Lead Further Demonstrated in Multi-Center Analysis of More Than 200 Cardiac Procedures
BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced positive safety and effectiveness data from a physician-sponsored U.S. study of the company’s Tempo Temporary Pacing Lead. Results from a multi-center retrospective analysis of 224 U.S. interventional cardiac procedures, including transcatheter aortic valve replacement (TAVR), confirm the Tempo ...
-
Andrew Cleeland joins atHeart Medical’s Board
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company’s Board of Directors. With over thirty years of experience, including specific expertise bringing game-changing technologies to market, Mr. ...
-
DurAVR accepted into TCT innovation session
Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces its submission at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference at Orlando, Florida, United States was accepted into the innovation session. The TCT conference, running from November 4 to 6, is the largest and most prestigious Interventional cardiology meeting held each year and will return to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you